

For Immediate Release

TSX Exchange Symbol: RVX

This press release is not for dissemination in the United States or through U.S. newswire services.

Resverlogix Closes US \$25M Financing

Calgary, AB June 8, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX: RVX) is pleased to announce that on June 7, 2007 it sold and issued to certain institutional investors, in the aggregate, US \$25 million of senior secured convertible promissory notes due June 6, 2012 (“Notes”) and accompanying warrants to purchase, in the aggregate, 529,350 common shares of Resverlogix (“Warrants”). The Notes are convertible into approximately 1.5 million Resverlogix common shares at a conversion price of CAD \$17.50 per share and the Warrants are priced at \$20.63 per common share. The Notes and Warrants are subject to certain adjustments and provisions as previously disclosed in the June 6, 2007 press release. Oppenheimer & Co. Inc. acted as placement agent for the offering.

The Notes, Warrants and the common shares underlying the Notes and Warrants will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States unless registered under the Securities Act of 1933, as amended or unless an exemption from registration is available. Also, unless permitted under Canadian securities legislation, the holders of the Notes, Warrants and common shares underlying the Notes and Warrants will not be able to trade the Notes, Warrants or common shares underlying the Notes and Warrants until October 8, 2007. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that enhance ApoA-I to address atherosclerosis, the main underlying cause of cardiovascular disease (CVD) and other vascular diseases such as Alzheimer's Disease (AD). The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Kelly McNeill

Chief Financial Officer
Resverlogix Corp.
Phone: 403-254-9252 ext. 233
Fax: 403-256-8495
Email: kelly@resverlogix.com

Theresa Kennedy

Vice President
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Suite 202

279 Midpark Way SE

Calgary AB T2X 1M2

P 403.254.9252

F 403.256.8495

info@resverlogix.com

Website: www.resverlogix.com